14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NVS vs GSK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over GSK plc (GSK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GSK carries 42.7/100 (HOLD) at $50.77 (10.2x Forward P/E, 30.5% operating margin).
Composite vs. Pillar Nuance: While GSK currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 30.5% operating margin) and revenue trajectory (+4.7% vs. +4.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GSK. Trailing 12-month operating profitability (NVS 34.0% vs GSK 30.5%) and valuation multiples (NVS 16.2x vs GSK 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment41.2% of Rev ($16.7B)
90D Engineering Disclosures0 Published
GSK Moat ProfileHigh-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $101.5B market capitalization and 30.5% operating margin.
OpEx & R&D Reinvestment43.3% of Rev ($14.5B)
90D Engineering Disclosures0 Published
Investor FAQ NVS vs GSK Key Questions & Quantitative Answers
As of Nov 16, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over GSK plc (GSK) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas GSK carries 42.7/100 (HOLD) at $50.77 (10.2x Forward P/E, 30.5% operating margin). Composite vs. Pillar Nuance: While GSK currently prints a higher short-term Unified Composite Score (42.7/100 HOLD vs. NVS 41.5/100 SELL), NVS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 30.5% operating margin) and revenue trajectory (+4.7% vs. +4.0% YoY).
NVS leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with GSK at +4.0% YoY revenue growth and -22.8% YoY earnings growth on $33.5B TTM revenue (73.8% gross margin, 30.5% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $33.5B for GSK. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 43.3% of Rev ($14.5B) (0 disclosures) for GSK.
GSK screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas GSK trades at 10.2x Forward P/E, 17.6x Trailing P/E, 6.41x PEG, and 3.0x EV/Revenue (34.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus GSK (28.3% ROE) capital efficiency.
In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, GSK carries 22.3% implied volatility (39th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.27β · 30% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.